- Report
- March 2024
- 196 Pages
Global
From €3263EUR$3,374USD£2,796GBP
€3625EUR$3,749USD£3,107GBP
- Report
- January 2024
- 200 Pages
Global
From €4835EUR$5,000USD£4,144GBP
- Report
- January 2024
- 150 Pages
Global
From €4690EUR$4,850USD£4,020GBP
- Report
- April 2024
- 94 Pages
Global
From €5415EUR$5,600USD£4,641GBP
- Report
- November 2023
- 180 Pages
Global
From €4739EUR$4,900USD£4,061GBP
- Report
- June 2023
- 600 Pages
Global
From €3481EUR$3,600USD£2,984GBP
- Report
- March 2024
- 194 Pages
Global
From €3263EUR$3,374USD£2,796GBP
€3625EUR$3,749USD£3,107GBP
- Report
- December 2023
- 100 Pages
Global
From €5754EUR$5,950USD£4,931GBP
- Report
- February 2024
- 175 Pages
Global
From €4835EUR$5,000USD£4,144GBP
- Report
- January 2024
- 175 Pages
Global
From €4835EUR$5,000USD£4,144GBP
- Report
- August 2023
- 147 Pages
Global
From €7253EUR$7,500USD£6,216GBP
- Report
- April 2024
- 30 Pages
Global
From €2659EUR$2,750USD£2,279GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1209EUR$1,250USD£1,036GBP
- Report
- August 2023
- 201 Pages
Global
From €7253EUR$7,500USD£6,216GBP
- Report
- October 2023
- 182 Pages
Global
From €4739EUR$4,900USD£4,061GBP
- Report
- October 2019
- 90 Pages
Global
From €5754EUR$5,950USD£4,931GBP
- Report
- October 2022
- 113 Pages
Global
From €4594EUR$4,750USD£3,937GBP
- Report
- August 2022
- 105 Pages
Global
From €4594EUR$4,750USD£3,937GBP
- Report
- February 2023
- 120 Pages
Global
From €7253EUR$7,500USD£6,216GBP
- Report
- March 2023
- 117 Pages
Global
From €4739EUR$4,900USD£4,061GBP
Somatostatin Analogs are a class of drugs used in the treatment of oncology. They are used to inhibit the release of hormones, such as growth hormone, which can be overproduced in certain types of cancer. Somatostatin Analogs are used to treat a variety of cancers, including neuroendocrine tumors, carcinoid tumors, and pancreatic islet cell tumors. They are also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin Analogs are administered either intravenously or subcutaneously, depending on the type of cancer being treated.
The Somatostatin Analogs market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of cancer, as well as the development of new and improved drugs. The market is expected to continue to grow in the coming years, as more drugs are developed and approved for use.
Some of the major companies in the Somatostatin Analogs market include Novartis, Pfizer, Merck, and Sanofi. Show Less Read more